Dongling Zou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1992477/publications.pdf

Version: 2024-02-01

		1163117	1281871	
15	710	8	11	
papers	citations	h-index	g-index	
10	1.0	1.0	0.5.4	
18	18	18	864	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Research, 2020, 48, 3816-3831.	14.5	430
2	The m6A eraser FTO facilitates proliferation and migration of human cervical cancer cells. Cancer Cell International, 2019, 19, 321.	4.1	113
3	microRNA arm-imbalance in part from complementary targets mediated decay promotes gastric cancer progression. Nature Communications, 2019, 10, 4397.	12.8	61
4	Long non-coding RNA LSINCT5 promotes ovarian cancer cell proliferation, migration and invasion by disrupting the CXCL12/CXCR4 signalling axis. Oncology Letters, 2018, 15, 7200-7206.	1.8	23
5	SOX4 maintains the stemness of cancer cells via transcriptionally enhancing HDAC1 revealed by comparative proteomics study. Cell and Bioscience, 2021, 11, 23.	4.8	20
6	Machine learning-based prediction of survival prognosis in cervical cancer. BMC Bioinformatics, 2021, 22, 331.	2.6	18
7	Correlation between subsets of tumor-infiltrating immune cells and risk stratification in patients with cervical cancer. PeerJ, 2019, 7, e7804.	2.0	16
8	Increased expression of Na+/H+ exchanger isoform 1 predicts tumor aggressiveness and unfavorable prognosis in epithelial ovarian cancer. Oncology Letters, 2018, 16, 6713-6720.	1.8	11
9	A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer. BMC Cancer, 2021, 21, 661.	2.6	8
10	Efficacy of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer in phase 3 PRIME study: A subgroup analysis by response to first-line platinum-based chemotherapy Journal of Clinical Oncology, 2022, 40, 5551-5551.	1.6	8
11	Preliminary results of niraparib and brivanib dual therapy evaluation in recurrent, metastatic and persistent cervical cancer (CQGOG0101): An open-label, phase II clinical trial Journal of Clinical Oncology, 2021, 39, e17506-e17506.	1.6	O
12	Association of alterations in DNA damage repair and Notch pathways with high tumor mutational burden in patients with cervical cancer Journal of Clinical Oncology, 2021, 39, e17511-e17511.	1.6	0
13	Efficacy and safety of PEGylated recombinant human granulocyte stimulating factor in the prevention of neutropenia during concurrent chemoradiotherapy Journal of Clinical Oncology, 2020, 38, e18018-e18018.	1.6	O
14	Randomized controlled trial of the efficacy of lymph node dissection on stage IIICr of cervical cancer (CQGOG0103) Journal of Clinical Oncology, 2022, 40, TPS5604-TPS5604.	1.6	0
15	Multi-omics characterization of productive HPV integration in cervical cancer Journal of Clinical Oncology, 2022, 40, e17508-e17508.	1.6	O